FDA Inspection 1086592 — Xeris Pharmaceuticals, Inc.
The FDA completed an inspection of Xeris Pharmaceuticals, Inc. on March 14, 2019 in Chicago, IL. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- March 14, 2019
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Chicago, IL (United States)
Additional Details
Sponsor, Contract Research Organization